Grant Info

Gabrielle’s Angel Foundation funds the nation’s best science in the fields of leukemia, lymphoma, and related cancers of the blood. Our latest grantees are listed here in our recent press release.

The Foundation not only funds conventional scientific research, but also projects that combine integrative (complementary) therapies or botanical agents. We focus on projects for cancer prevention, detection and treatment that are most likely to be translated into clinical trials within a 3 – 5 year period. These Medical Research Awards, distributed on a yearly basis, each total $225,000.00 and are given over a three-year period. The top research institutions in the nation are solicited by invitation-only and, once the applications are received, undergo rigorous peer review by the Foundation’s ten-member Medical Advisory Board. This panel of experts, led by Stephen D. Nimer, M.D., Director of The University of Miami's Sylvester Comprehensive Cancer Center, selects only the crème de la crème for funding. Nearly two thirds of our grantees are able to obtain further funding at the federal level thanks to their early career support from Gabrielle’s Angel Foundation. In recent years, the Foundation has expanded its reach to include the funding of select pediatric oncology initiatives, music therapy programs, and international projects. Gabrielle’s Angel Foundation has supported more than 130 leading junior investigators totaling $25 million and maintains its status as one of the nation’s largest non-governmental sources of grant support for blood cancer research.

In 2012, two teams of former grantees received Collaborative Grant Awards totaling $800,000 made possible by a generous gift from the Marc Rich Foundation. Each team will receive $400,000 over two years. Medical Advisory Board chair Stephen D. Nimer, M.D. remarked, “What is particularly exciting about these new collaborative grants is that they not only prove the value of the initial investment, they bring scientists and institutions together to significantly accelerate and broaden the impact of their work.” Ari Melnick, M.D. of Weill Cornell Medical College will work alongside fellow New York colleague Ross Levine, M.D. of Memorial Sloan-Kettering Cancer Center and Chuan He, Ph.D. from The University of Chicago. Their study, entitled “Decoding the hydroxymethylome of IDH and TET mutant acute leukemias,” will look to identify the molecular cause of a new type of acute myelogenous leukemia. Anthony Letai, M.D. of Boston’s Dana-Farber Cancer Institute will work with Sloan-Kettering’s Scott Armstrong, M.D. on a project were they propose “a completely novel approach to identifying the chemotherapy resistant subsets in [acute myelogenous] leukemia patient samples, identifying the mechanisms making them resistant to chemotherapy, and targeting those mechanisms.”

Applicants may download and reference these Frequently Asked Questions while working on their submissions.

Because our grant solicitation process is conducted by invitation-only, Gabrielle's Angel Foundation does not publish our application materials online. For more information, please contact Christa Justus in the Foundation office.